|Articles|July 9, 2014

Special Reports

  • Hematologic Malignancies
  • Volume 1
  • Issue 1

Comorbidities, Age, and Outcomes Among Intensively Treated Patients With AML

Timothy S. Pardee, MD, discusses comorbidities, age, and outcomes among intensively treated patients with acute myeloid leukemia (AML).

Timothy S. Pardee, MD, assistant professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, discusses comorbidities, age, and outcomes among intensively treated patients with acute myeloid leukemia (AML).

Read about new treatments for AML > >

Articles in this issue

almost 12 years ago

In the Pipeline: Potential New Treatments for AML

almost 12 years ago

Epidemiology in B-Cell Malignancies

almost 12 years ago

Pathogenesis of Follicular Lymphoma

almost 12 years ago

Resistance to Ibrutinib

almost 12 years ago

IPI-145 and ABT-199 for Lymphoid Malignancies

almost 12 years ago

BCL-2 Inhibitor Combo May Offer Remissions in CLL

almost 12 years ago

In Practice: Challenges in Treating Patients With Relapsed or Refractory CLL

Newsletter

Subscribe

Related Content

Latest CME

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology Society
Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Seth A. Wander, MD, PhD; Girish Kunapareddy, MD

View more
Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Iowa
Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Iowa

Virginia Kaklamani, MD, DSc; Jack W. Erter III, MD, MMHC

View more
Arkansas Association of Cancer Professionals
Virtual Event

Arkansas Association of Cancer Professionals

2 Sessions are Available!

View more
Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology Society
Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology Society

Seth A. Wander, MD, PhD; Kit Lu, MD

View more
Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics, and Beyond
In-Person Event

Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics, and Beyond

May 22, 2026

Register now!
Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Minnesota
Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Minnesota

Neil M. Iyengar, MD; Kimberly Ku, MD

View more
Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Texas
Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Texas

Sheila Donnelly, MD; Virginia Kaklamani, MD, DSc

View more
Updates from Berlin: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us
Virtual Event

Updates from Berlin: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

May 27, 2026

View more
Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®
Multimedia

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

View more
Go to PER in Chicago
In-Person + Virtual Event

Go to PER in Chicago

May 29-31, 2026

View more
Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice Society
Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice Society

Seth A. Wander, MD, PhD; Kamel Abou Hussein, MD

View more
Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Washington
Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Washington

Alison K. Conlin, MD; Neil M. Iyengar, MD

View more
Updates from Chicago: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us
Virtual Event

Updates from Chicago: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

June 8, 2026

View more
Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Wyoming & Montana
Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Wyoming & Montana

Yan Ji, MD; Neil M. Iyengar, MD

View more
Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – North Carolina
Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – North Carolina

Girish Kunapareddy, MD; Sara M. Tolaney, MD, MPH

View more
Iowa Oncology Society
Virtual Event

Iowa Oncology Society

1 Session is Available!

View more
Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society
Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Seth A. Wander, MD, PhD; Ruta D. Rao, MD

View more
Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society
Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Marla D. Lipsyc-Sharf, MD; Richard Zelkowitz, MD

View more
Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society
Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Seth A. Wander, MD, PhD; Kate Baxstrom, MD

View more
Kansas Society of Clinical Oncology
Virtual Event

Kansas Society of Clinical Oncology

1 Session is Available!

View more
Louisiana Oncology Society
Virtual Event

Louisiana Oncology Society

1 Session is Available!

View more
Missouri Oncology Society
Virtual Event

Missouri Oncology Society

1 Session is Available!

View more
New Mexico Society of Clinical Oncology
Virtual Event

New Mexico Society of Clinical Oncology

1 Session is Available!

View more
Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer
Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

View more
Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates
Video

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

View more
25th Annual International Congress on the Future of Breast Cancer® East
In-Person + Virtual Event

25th Annual International Congress on the Future of Breast Cancer® East

July 10-11, 2026

View more
Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment
Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

View more
Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC
Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

View more
Establishing the Rationale for ADC and ICI Combinations in TNBC
Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

View more
Dissecting Clinical Trial and Real-World Data for ADCs in TNBC
Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

View more
Breaking Down the Rationale for Targeting TROP2 in TNBC
Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

View more
Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC
Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

View more
24th Annual International Congress on the Future of Breast Cancer® East
Video

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

View more
PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing
Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

View more
Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC
Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

View more
Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer
Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

View more
(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes
Video

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

View more